Gemini Therapeutics (NASDAQ:GMTX) Trading Down 1.8% – Here’s Why

Gemini Therapeutics, Inc. (NASDAQ:GMTX) fell 1.8% on Friday . The stock traded as low as $61.9150 and last traded at $63.35. 788,480 shares were traded during mid-day trading, an increase of 317% from the average session volume of 189,291 shares. The stock had previously closed at $64.48.

Gemini Therapeutics Price Performance

The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -63.35 and a beta of -0.12. The company’s fifty day moving average price is $77.24 and its 200-day moving average price is $75.13.

Gemini Therapeutics Company Profile

Gemini Therapeutics (NASDAQ:GMTX) is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company’s approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.

Gemini’s lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.